Market Cap 408.17M
Revenue (ttm) 79.87M
Net Income (ttm) -51.51M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -64.49%
Debt to Equity Ratio 0.62
Volume 308,400
Avg Vol 185,820
Day's Range N/A - N/A
Shares Out 52.87M
Stochastic %K 68%
Beta 2.47
Analysts Sell
Price Target $5.17

Company Profile

Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases. The company operates in two segments, Surgical Glaucoma and Dry Eye. Its products include OMNI surgical system, an implant-free, handheld, single-use, therapeutic technology that enables ophthalmic surgeons to perform a comprehensive procedure indicated to reduce intraocular pressure in adult patients wi...

Industry: Medical Devices
Sector: Healthcare
Phone: 877 266 1144
Fax: 650 352 4401
Address:
4040 Campbell Avenue, Suite 100, Menlo Park, United States
Bazzzigar
Bazzzigar Nov. 13 at 6:02 PM
$SGHT AEMD
0 · Reply
lawson
lawson Nov. 12 at 9:03 PM
$SGHT Nice recovery! $7.72 + $0.68 + (9.66%)
0 · Reply
lawson
lawson Nov. 12 at 7:15 PM
$SGHT Feeling bad for those who bought at $7.50 - $8. Hope it bounces
0 · Reply
SlatsMcSlappy
SlatsMcSlappy Nov. 12 at 3:13 PM
$SGHT Every day is a payday with this stock
0 · Reply
lawson
lawson Nov. 11 at 9:03 PM
$SGHT SGHT UP BIG, AGAIN $7.04 + $0.52 + 7.98%
0 · Reply
topstockalerts
topstockalerts Nov. 11 at 5:19 PM
Shares of Sight Sciences rose Tuesday after the company announced results from three published studies highlighting the effectiveness of its OMNI device in treating glaucoma. The eye care firm, which develops interventional technologies for ocular diseases, said the studies showed sustained reductions in intraocular pressure (IOP) and decreased medication dependence among patients treated with OMNI. In a 24-month prospective study, standalone OMNI treatment lowered mean IOP from 26.1 mmHg to 10.6 mmHg at two years, with two-thirds of patients medication-free at 24 months. Another study involving nearly 13,000 African-American patient eyes found that OMNI, when used alongside cataract surgery, produced the highest proportion of patients achieving at least a 20% IOP reduction compared with other minimally invasive glaucoma surgery (MIGS) devices. $SGHT
0 · Reply
lawson
lawson Nov. 11 at 3:38 PM
$SGHT SGHT is finally a sellable company. Hopefully, B&L, Glaukos, Alcon or another optho-pharma company will swoop in and pay $10-$12. Too bad for those that paid much higher. IPO = $24
0 · Reply
lawson
lawson Nov. 11 at 1:52 PM
$SGHT This guy seems to buy ahead of good news. He bought 1.2 million shares in June. ENCRANTZ STAFFAN Director and Beneficial Owner of more than 10% of a Class of Security”
0 · Reply
lawson
lawson Nov. 11 at 1:20 PM
$SGHT https://finance.yahoo.com/news/peer-reviewed-publications-highlight-effectiveness-120000548.html
0 · Reply
lawson
lawson Nov. 11 at 1:19 PM
$SGHT MORE GREAT NEWS Medication Usage in Cataract Combination Procedures, Standalone Procedures, and in African Americans. “We are proud to continuously support the study of interventional glaucoma treatment, especially in highlighting critical groups of patients that may benefit from active surgical interventions. These results demonstrate that when surgeons are given the right solutions, they are able to reduce a patient’s intraocular eye pressure (IOP) and reliance on medication and maintain those reductions over an extended period of time, 24 months or 36 months,” said Paul Badawi, Founder and Chief Executive Officer of Sight Sciences. In a 24-month prospective study of 18 eyes with medication washout at baseline, 12 and 24 months, of standalone OMNI use, mean baseline IOP of 26.1 mmHg was reduced an average of 9.7mmHg at 12 months and 10.6 mmHg at 24 months (both p<.001), while mean medications were reduced from 1.8 to 0.9 and 0.5 (both p<.001) at months 12 and 24, respectively
0 · Reply
Latest News on SGHT
Sight Sciences, Inc. (SGHT) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 10:16 PM EST - 7 days ago

Sight Sciences, Inc. (SGHT) Q3 2025 Earnings Call Transcript


Sight Sciences, Inc. (SGHT) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 6:48 AM EDT - 3 months ago

Sight Sciences, Inc. (SGHT) Q2 2025 Earnings Call Transcript


Sight Sciences, Inc. (SGHT) Q1 2025 Earnings Call Transcript

May 11, 2025, 1:26 AM EDT - 6 months ago

Sight Sciences, Inc. (SGHT) Q1 2025 Earnings Call Transcript


Sight Sciences Appoints Gary Burbach to its Board of Directors

Apr 22, 2025, 4:05 PM EDT - 7 months ago

Sight Sciences Appoints Gary Burbach to its Board of Directors


Sight Sciences, Inc. (SGHT) Q3 2024 Earnings Call Transcript

Nov 9, 2024, 1:32 PM EST - 1 year ago

Sight Sciences, Inc. (SGHT) Q3 2024 Earnings Call Transcript


Sight Sciences, Inc. (SGHT) Q2 2024 Earnings Call Transcript

Aug 3, 2024, 3:12 AM EDT - 1 year ago

Sight Sciences, Inc. (SGHT) Q2 2024 Earnings Call Transcript


Sight Sciences, Inc. (SGHT) Q1 2024 Earnings Call Transcript

May 5, 2024, 1:58 AM EDT - 1 year ago

Sight Sciences, Inc. (SGHT) Q1 2024 Earnings Call Transcript


Sight Sciences, Inc. (SGHT) Q4 2023 Earnings Call Transcript

Mar 7, 2024, 10:56 PM EST - 1 year ago

Sight Sciences, Inc. (SGHT) Q4 2023 Earnings Call Transcript


Bazzzigar
Bazzzigar Nov. 13 at 6:02 PM
$SGHT AEMD
0 · Reply
lawson
lawson Nov. 12 at 9:03 PM
$SGHT Nice recovery! $7.72 + $0.68 + (9.66%)
0 · Reply
lawson
lawson Nov. 12 at 7:15 PM
$SGHT Feeling bad for those who bought at $7.50 - $8. Hope it bounces
0 · Reply
SlatsMcSlappy
SlatsMcSlappy Nov. 12 at 3:13 PM
$SGHT Every day is a payday with this stock
0 · Reply
lawson
lawson Nov. 11 at 9:03 PM
$SGHT SGHT UP BIG, AGAIN $7.04 + $0.52 + 7.98%
0 · Reply
topstockalerts
topstockalerts Nov. 11 at 5:19 PM
Shares of Sight Sciences rose Tuesday after the company announced results from three published studies highlighting the effectiveness of its OMNI device in treating glaucoma. The eye care firm, which develops interventional technologies for ocular diseases, said the studies showed sustained reductions in intraocular pressure (IOP) and decreased medication dependence among patients treated with OMNI. In a 24-month prospective study, standalone OMNI treatment lowered mean IOP from 26.1 mmHg to 10.6 mmHg at two years, with two-thirds of patients medication-free at 24 months. Another study involving nearly 13,000 African-American patient eyes found that OMNI, when used alongside cataract surgery, produced the highest proportion of patients achieving at least a 20% IOP reduction compared with other minimally invasive glaucoma surgery (MIGS) devices. $SGHT
0 · Reply
lawson
lawson Nov. 11 at 3:38 PM
$SGHT SGHT is finally a sellable company. Hopefully, B&L, Glaukos, Alcon or another optho-pharma company will swoop in and pay $10-$12. Too bad for those that paid much higher. IPO = $24
0 · Reply
lawson
lawson Nov. 11 at 1:52 PM
$SGHT This guy seems to buy ahead of good news. He bought 1.2 million shares in June. ENCRANTZ STAFFAN Director and Beneficial Owner of more than 10% of a Class of Security”
0 · Reply
lawson
lawson Nov. 11 at 1:20 PM
$SGHT https://finance.yahoo.com/news/peer-reviewed-publications-highlight-effectiveness-120000548.html
0 · Reply
lawson
lawson Nov. 11 at 1:19 PM
$SGHT MORE GREAT NEWS Medication Usage in Cataract Combination Procedures, Standalone Procedures, and in African Americans. “We are proud to continuously support the study of interventional glaucoma treatment, especially in highlighting critical groups of patients that may benefit from active surgical interventions. These results demonstrate that when surgeons are given the right solutions, they are able to reduce a patient’s intraocular eye pressure (IOP) and reliance on medication and maintain those reductions over an extended period of time, 24 months or 36 months,” said Paul Badawi, Founder and Chief Executive Officer of Sight Sciences. In a 24-month prospective study of 18 eyes with medication washout at baseline, 12 and 24 months, of standalone OMNI use, mean baseline IOP of 26.1 mmHg was reduced an average of 9.7mmHg at 12 months and 10.6 mmHg at 24 months (both p<.001), while mean medications were reduced from 1.8 to 0.9 and 0.5 (both p<.001) at months 12 and 24, respectively
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Nov. 11 at 12:20 PM
$SGHT Sight Sciences Reports Peer-Reviewed Studies Showing OMNI Surgical System With TruSync Reduces IOP And Medication Use In Cataract-Combination, Standalone, And African American Patients
0 · Reply
JarvisFlow
JarvisFlow Nov. 10 at 6:13 PM
Morgan Stanley has updated their rating for Sight Sciences ( $SGHT ) to Equal-Weight with a price target of 6.
0 · Reply
lawson
lawson Nov. 8 at 1:08 AM
$SGHT Another great day for SGHT. Up 100% over the last month
0 · Reply
JarvisFlow
JarvisFlow Nov. 7 at 12:47 PM
Piper Sandler has adjusted their stance on Sight Sciences ( $SGHT ), setting the rating to Neutral with a target price of 4 → 5.
0 · Reply
d_risk
d_risk Nov. 7 at 12:17 AM
$SGHT - Sight Sciences Inc. Common Stock - 10Q - Updated Risk Factors SGHT warns that losing or failing to secure third-party coverage and reimbursement for its Surgical Glaucoma or Dry Eye products could hit its business and financials hard. #MedicalDevices #SurgicalProducts #HealthcareCoverage #ReimbursementRisk #Ophthalmology 🟢 Added 🟠 Removed https://d-risk.ai/SGHT/10-Q/2025-11-06
0 · Reply
lawson
lawson Oct. 26 at 6:30 PM
$SGHT Recent gain in the PPS due to only 2 MACS approving TearCare for reimbursement. The 2 MACS represent only 30% of the population. When the other MACS approve (monkey see, monkey do), the PPS will pop to $8+
0 · Reply
Winning_calls
Winning_calls Oct. 24 at 1:19 PM
$SGHT 👋🫡
0 · Reply
anachartanalyst
anachartanalyst Oct. 21 at 5:02 PM
$SGHT https://anachart.com/wp-content/uploads/ana_temp/1761066143_soc-img.jpg
0 · Reply
JarvisFlow
JarvisFlow Oct. 21 at 2:55 PM
Lake Street updates rating for Sight Sciences ( $SGHT ) to Buy, target set at 5 → 7.
0 · Reply
Raxothus
Raxothus Oct. 20 at 7:48 PM
EOD CONTINUATION FOLLOW-UP – 10/17/25 Tracking continuation watchlist from yesterday based on intraday highs vs. close ❌ $SPAI – Dropped from 9.00 to 7.38 (–18%), full fade after strong prior session. Failed continuation. ⚠️ $KZR – Moving sideways, no clear trend. Neutral. ✅ $DMRC – Closed 8.60, hit HOD 9.27 (+7.8%), solid continuation with controlled pullback. ✅ $SGHT – Closed 4.60, reached 5.14 (+11.7%), clean follow-through, strong intraday action. ✅ $VANI – Closed 1.70, now 1.83 (+7.6%), gradual continuation move. Recap: 5 total → 3 winners ($DMRC, $SGHT, $VANI), 1 fail ($SPAI), 1 neutral → 60% accuracy Leaders: $SGHT showed strongest continuation, $DMRC and $VANI held structure well; $SPAI was the only full fade. #vwap #smallcaps #daytrading #eodfollowup #continuation #snipersetup #accountability
0 · Reply
Winning_calls
Winning_calls Oct. 20 at 3:14 PM
$SGHT 👋👋👋🤞join the team.
0 · Reply
Winning_calls
Winning_calls Oct. 20 at 1:20 PM
$SGHT 🤞🤞
0 · Reply